Vitiligo is an acquired, often familial, melanocytopenic disorder that produces focal depigmentation of the skin.
About half of the patients has onset of lesion before the age of 20.
It is a progressive disease wherein spontaneous repigmentation may occur within 6 months.
Precipitating factors include emotional stress, sunburn, chemical exposure, skin trauma, inflammation, irritation or rash that may precede the lesions by 2-3 months.
Lesions are white-colored macules or patches with well-defined borders and otherwise normal skin surface.
Melanocyte-keratinocyte transplantation procedure (MKTP) confers satisfactory long-term repigmentation in patients with leukoderma, with repigmentation lasting for at least 72 months, reports a recent study.
The use of topical ruxolitinib 1.5% cream, a Janus kinase (JAK) inhibitor, delivers significant repigmentation in facial vitiligo, promising a new treatment for the said skin disease, reports a recent study.
Patients who underwent haematopoietic stem cell transplantation (HSCT) develop vitiligo at a significantly higher rate than controls, according to a new study. Moreover, allogeneic HSCT and bone marrow-sourced stem cells are independently tied to increased risk of developing vitiligo after HSCT.